Regulatory milestones

Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) lost $0.21 to $6.41 last week after FDA's Oncologic Drugs Advisory Committee said it meet May 2 to discuss an NDA for Tivopath tivozanib to treat advanced renal cell carcinoma (RCC). The PDUFA date is July 28.